Literature DB >> 23580662

Downregulation of FOXP1 is required during germinal center B-cell function.

Ainara Sagardoy1, Jose I Martinez-Ferrandis, Sergio Roa, Karen L Bunting, María Angela Aznar, Olivier Elemento, Rita Shaknovich, Lorena Fontán, Vicente Fresquet, Ignacio Perez-Roger, Eloy F Robles, Linde De Smedt, Xavier Sagaert, Ari Melnick, Jose A Martinez-Climent.   

Abstract

B-cell maturation and germinal center (GC) formation are dependent on the interplay between BCL6 and other transcriptional regulators. FOXP1 is a transcription factor that regulates early B-cell development, but whether it plays a role in mature B cells is unknown. Analysis of human tonsillar B-cell subpopulations revealed that FOXP1 shows the opposite expression pattern to BCL6, suggesting that FOXP1 regulates the transition from resting follicular B cell to activated GC B cell. Chromatin immunoprecipitation-on-chip and gene expression assays on B cells indicated that FOXP1 acts as a transcriptional activator and repressor of genes involved in the GC reaction, half of which are also BCL6 targets. To study FOXP1 function in vivo, we developed transgenic mice expressing human FOXP1 in lymphoid cells. These mice exhibited irregular formation of splenic GCs, showing a modest increase in naïve and marginal-zone B cells and a significant decrease in GC B cells. Furthermore, aberrant expression of FOXP1 impaired transcription of noncoding γ1 germline transcripts and inhibited efficient class switching to the immunoglobulin G1 isotype. These studies show that FOXP1 is physiologically downregulated in GC B cells and that aberrant expression of FOXP1 impairs mechanisms triggered by B-cell activation, potentially contributing to B-cell lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23580662      PMCID: PMC3713421          DOI: 10.1182/blood-2012-10-462846

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.

Authors:  Xavier Sagaert; Pascale de Paepe; Louis Libbrecht; Vera Vanhentenrijk; Gregor Verhoef; Jose Thomas; Iwona Wlodarska; Christiane De Wolf-Peeters
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

2.  Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.

Authors:  Alison H Banham; Joseph M Connors; Philip J Brown; Jacqueline L Cordell; German Ott; Gayatri Sreenivasan; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

3.  FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations.

Authors:  I Wlodarska; E Veyt; P De Paepe; P Vandenberghe; P Nooijen; I Theate; L Michaux; X Sagaert; P Marynen; A Hagemeijer; C De Wolf-Peeters
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

4.  Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry.

Authors:  Hiroshi Kubo; Masakazu Shimizu; Yuji Taya; Takeshi Kawamoto; Masahiko Michida; Emi Kaneko; Akira Igarashi; Masahiro Nishimura; Kazumi Segoshi; Yoshihito Shimazu; Koichiro Tsuji; Takaaki Aoba; Yukio Kato
Journal:  Genes Cells       Date:  2009-02-17       Impact factor: 1.891

Review 5.  B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.

Authors:  Weimin Ci; Jose M Polo; Ari Melnick
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

6.  t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma.

Authors:  James A L Fenton; Ed Schuuring; Sharon L Barrans; Alison H Banham; Sara J Rollinson; Gareth J Morgan; Andrew S Jack; J Han J M van Krieken; Philip M Kluin
Journal:  Genes Chromosomes Cancer       Date:  2006-02       Impact factor: 5.006

7.  T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.

Authors:  B Streubel; U Vinatzer; A Lamprecht; M Raderer; A Chott
Journal:  Leukemia       Date:  2005-04       Impact factor: 11.528

8.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

Authors:  Stefano Monti; Kerry J Savage; Jeffery L Kutok; Friedrich Feuerhake; Paul Kurtin; Martin Mihm; Bingyan Wu; Laura Pasqualucci; Donna Neuberg; Ricardo C T Aguiar; Paola Dal Cin; Christine Ladd; Geraldine S Pinkus; Gilles Salles; Nancy Lee Harris; Riccardo Dalla-Favera; Thomas M Habermann; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

9.  Control of inflammation, cytokine expression, and germinal center formation by BCL-6.

Authors:  A L Dent; A L Shaffer; X Yu; D Allman; L M Staudt
Journal:  Science       Date:  1997-04-25       Impact factor: 47.728

10.  FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.

Authors:  Alison Goatly; Chris M Bacon; Shotaro Nakamura; Hongtao Ye; Insun Kim; Philip J Brown; Agnès Ruskoné-Fourmestraux; Pascale Cervera; Berthold Streubel; Alison H Banham; Ming-Qing Du
Journal:  Mod Pathol       Date:  2008-05-16       Impact factor: 7.842

View more
  27 in total

1.  Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.

Authors:  K K Wong; D M Gascoyne; P J Brown; E J Soilleux; C Snell; H Chen; L Lyne; C H Lawrie; R D Gascoyne; L M Pedersen; M B Møller; K Pulford; D Murphy; T M Green; A H Banham
Journal:  Leukemia       Date:  2013-07-25       Impact factor: 11.528

2.  FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Michal Mokry; Ruben van Boxtel; Jan Koster; Paul J Coffer; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2014-09-29       Impact factor: 22.113

3.  PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.

Authors:  Marién Pascual; María Mena-Varas; Eloy Francisco Robles; Maria-Jose Garcia-Barchino; Carlos Panizo; Sandra Hervas-Stubbs; Diego Alignani; Ainara Sagardoy; Jose Ignacio Martinez-Ferrandis; Karen L Bunting; Stephen Meier; Xavier Sagaert; Davide Bagnara; Elizabeth Guruceaga; Oscar Blanco; Jon Celay; Alvaro Martínez-Baztan; Noelia Casares; Juan José Lasarte; Thomas MacCarthy; Ari Melnick; Jose Angel Martinez-Climent; Sergio Roa
Journal:  Blood       Date:  2019-04-11       Impact factor: 22.113

4.  Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.

Authors:  Joseph D Dekker; Daechan Park; Arthur L Shaffer; Holger Kohlhammer; Wei Deng; Bum-Kyu Lee; Gregory C Ippolito; George Georgiou; Vishwanath R Iyer; Louis M Staudt; Haley O Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

5.  miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1.

Authors:  Marek Mraz; Liguang Chen; Laura Z Rassenti; Emanuela M Ghia; Hongying Li; Kristen Jepsen; Erin N Smith; Karen Messer; Kelly A Frazer; Thomas J Kipps
Journal:  Blood       Date:  2014-05-01       Impact factor: 22.113

6.  FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.

Authors:  Matthew P Walker; Charles M Stopford; Maria Cederlund; Fang Fang; Christopher Jahn; Alex D Rabinowitz; Dennis Goldfarb; David M Graham; Feng Yan; Allison M Deal; Yuri Fedoriw; Kristy L Richards; Ian J Davis; Gilbert Weidinger; Blossom Damania; Michael B Major
Journal:  Sci Signal       Date:  2015-02-03       Impact factor: 8.192

7.  The forkhead transcription factor FOXP1 represses human plasma cell differentiation.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Michal Mokry; Ruben van Boxtel; Menno C van Zelm; Paul Coffer; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2015-08-19       Impact factor: 22.113

Review 8.  Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Authors:  Ricardo García-Muñoz; Luis Llorente
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

Review 9.  Forkhead box transcription factors as context-dependent regulators of lymphocyte homeostasis.

Authors:  Dietmar M W Zaiss; Paul J Coffer
Journal:  Nat Rev Immunol       Date:  2018-11       Impact factor: 53.106

10.  N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.

Authors:  Philip J Brown; Duncan M Gascoyne; Linden Lyne; Hayley Spearman; Suet Ling Felce; Nora McFadden; Probir Chakravarty; Sharon Barrans; Steven Lynham; Dinis P Calado; Malcolm Ward; Alison H Banham
Journal:  Haematologica       Date:  2016-04-07       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.